Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Pharmanet Development Grp (MM) Charts. Click Here for more Pharmanet Development Grp (MM) Charts.](/p.php?pid=staticchart&s=N%5EPDGI&p=8&t=15)
PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of
drug development services, today announced that it will release its
first quarter 2007 financial results on Thursday, May 3, 2007 before the
market opens. Following the pre-market release, the Company plans to
host a conference call and webcast to review these results at 8:30 a.m.
EDT.
First Quarter 2007 Earnings Conference Call:
When: Thursday, May 3, 2007 at 8:30 a.m. EDT
Dial-in: (888) 396-2386 for U.S.
(617) 847-8712 for International
Pass code: 40038227
Dial-in Replay: (888) 286-8010 for U.S.
(617) 801-6888 for International
Pass code: 83884265
Available approximately two hours after the call
through Thursday, May 10, 2007
Webcast: Please visit www.pharmanet.com
and select the investor tab to access the webcast or access the link
directly at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=124176
&eventID=1523683. (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the
extra space if one exists.) The archived webcast will be available for
approximately thirty (30) days following the conference call.
About PharmaNet Development Group,
Inc.
PharmaNet Development Group, a global drug development company, provides
a comprehensive range of services to the pharmaceutical, biotechnology,
generic drug, and medical device industries. The Company offers
clinical-development solutions including early and late stage consulting
services, Phase l clinical studies and bioanalytical analyses, and Phase
Il, III and IV clinical development programs. With approximately 2,200
employees and more than 35 facilities throughout the world, PharmaNet is
a recognized leader in outsourced clinical development. For more
information, please visit our website at www.pharmanet.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally, words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause or
contribute to such differences include, but are not limited to, industry
trends and information; the Company's ability to determine its
impairment charges and costs of discontinued operations; whether the
Company will achieve its estimated value relating to discontinued
operations; developments with respect to the SEC's inquiry and
securities class action lawsuits and derivative lawsuits; the Company’s
ability to successfully achieve and manage the technical requirements of
specialized clinical trial services, while complying with applicable
rules and regulations; regulatory changes; changes affecting the
clinical research industry; a reduction of outsourcing by pharmaceutical
and biotechnology companies; the Company’s
ability to compete internationally in attracting clients in order to
develop additional business; the Company’s
evaluation of its backlog and the potential cancellation of contracts;
its ability to retain and recruit new employees; its clients' ability to
provide the drugs and medical devices used in its clinical trials; the
Company’s future stock price; the Company’s
assessment of its effective tax rate and tax allowance; the Company’s
financial guidance; the Company’s future
effective tax rate; the Company’s anticipated
capital expenditures; the Company’s costs
associated with compliance of Section 404 of the Sarbanes-Oxley Act; the
impact on the Company of foreign currency transaction costs and the
effectiveness of any hedging strategies that it implements; and the
national and international economic climate as it affects drug
development operations.
Further information can be found in the Company’s
risk factors contained in its Annual Report on Form 10-K for the year
ended December 31, 2006 and its most recent Quarterly Report on Form
10-Q. The Company does not undertake to update the disclosures made
herein, and you are urged to read our filings with the Securities and
Exchange Commission.